Cutaneous adverse effects during ipilimumab treatment for metastatic melanoma: a prospective study

Dika, Emi; Ravaioli, Giulia Maria; Fanti, Pier ­Alessandro; Piraccini, Bianca Maria; Lambertini, Martina; Chessa, Marco Adriano; Baraldi, Carlotta; Ribero, Simone; Ardizzoni, Andrea; Melotti, Barbara; Patrizi, Annalisa

doi:10.1684/ejd.2017.3023

Cited by 45 publications

(40 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Newly developed drugs, such as anticancer target therapies, also have the potential to induce SJS/TEN [ 54 ]. SJS/TEN induced by monoclonal antibodies targeting the coinhibitory immune checkpoint with antiprogrammed death-1 (PD-1) (nivolumab) and anticytotoxic T-lymphocyte-associated protein 4 (CTLA-4) (ipilimumab) has likewise been reported [ 55 , 56 ]. Proton pump inhibitors, meanwhile, have been known to induce type I hypersensitivity reactions, but they carry some risk of inducing life-threatening type IV hypersensitivity reactions as well [ 57 ].…”

Section: Clinical Perspectives and Variabilities In Severe Drug Hymentioning

confidence: 99%

An Updated Review of the Molecular Mechanisms in Drug Hypersensitivity

Chen

Abe

Pan

et al. 2018

Journal of Immunology Research

119

View full text Add to dashboard Cite

Drug hypersensitivity may manifest ranging from milder skin reactions (e.g., maculopapular exanthema and urticaria) to severe systemic reactions, such as anaphylaxis, drug reactions with eosinophilia and systemic symptoms (DRESS)/drug-induced hypersensitivity syndrome (DIHS), or Stevens–Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN). Current pharmacogenomic studies have made important strides in the prevention of some drug hypersensitivity through the identification of relevant genetic variants, particularly for genes encoding drug-metabolizing enzymes and human leukocyte antigens (HLAs). The associations identified by these studies are usually drug, phenotype, and ethnic specific. The drug presentation models that explain how small drug antigens might interact with HLA and T cell receptor (TCR) molecules in drug hypersensitivity include the hapten theory, the p-i concept, the altered peptide repertoire model, and the altered TCR repertoire model. The broad spectrum of clinical manifestations of drug hypersensitivity involving different drugs, as well as the various pathomechanisms involved, makes the diagnosis and management of it more challenging. This review highlights recent advances in our understanding of the predisposing factors, immune mechanisms, pathogenesis, diagnostic tools, and therapeutic approaches for drug hypersensitivity.

show abstract

Section: Clinical Perspectives and Variabilities In Severe Drug Hymentioning

confidence: 99%

An Updated Review of the Molecular Mechanisms in Drug Hypersensitivity

Chen

Abe

Pan

et al. 2018

Journal of Immunology Research

119

View full text Add to dashboard Cite

show abstract

“…In addition, these patients also had erythema multiforme, folliculitis, acneiform eruption, and Stevens-Johnson syndrome. 9 …”

Section: Discussionmentioning

confidence: 99%

Nivolumab-induced systemic vasculitis

2018

View full text Add to dashboard Cite

“…1 Cutaneous immune-related adverse events associated with ipilimumab are common and vary from mild to life threatening. 2 Here, we report a case of ipilimumab-induced bullous pemphigoid after unsuccessful treatment with pembrolizumab.…”

Section: Introductionmentioning

confidence: 91%